Free radicals in Parkinson's disease

Journal of Neurology, Supplement

Volumn 249, Issue 2, 2002, Pages

  Koutsilieri, Eleni ^a   Scheller, C ^a   Grunblatt E ^a   Nara, K ^a   Li, J ^a   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cell death; Cytokines; Microglia; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; CYTOCHROME P450 1A1; DOPAMINE; FREE RADICAL; GAMMA INTERFERON; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NITRIC OXIDE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

AGING; APOPTOSIS; CELL ACTIVATION; CONFERENCE PAPER; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ELECTRON TRANSPORT; GLYCATION; HUMAN; LEWY BODY; MICROGLIA; MITOCHONDRIAL RESPIRATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FREE RADICALS; HUMANS; MICROGLIA; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0036039058     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Brain peroxidase and catalase in Parkinson disease
2. The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study
3. Oxidative stress: Its role in the pathogenesis of amyotrophic lateral sclerosis
4. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study
5. Platelet mitochondrial respiratory chain function in Parkinson's disease
6. Superoxide dismutase activity in early and advanced Parkinson's disease
7. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
8. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
9. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease
10. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
11. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
12. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
13. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
14. Alpha-tocopherol levels in brain are not altered in Parkinson's disease
15. Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage?
16. Impaired iron homeostasis in Parkinson's disease
17. Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease
18. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids
19. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: Effect of R-apomorphine
20. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease
21. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
22. Oxidative stress and the pathogenesis of Parkinson's disease
23. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease
24. Glutathione peroxidase activity in Parkinson's disease brain
25. Microglia: A sensor for pathological events in the CNS
26. Platelet mitochondrial function in Parkinson's disease
27. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease
28. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
29. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
30. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
31. Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients
32. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
33. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease
34. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
35. Crosslinking of alpha-synuclein by advanced glycation endproducts - An early pathophysiological step in Lewy body formation?
36. Cytokines in Parkinson's disease
37. Oxidation reactions in Parkinson's disease
38. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary
39. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type
40. CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies
41. Is there neuroprotection in Parkinson syndrome?
42. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
43. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
44. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
45. Reduced intravenous glutathione in the treatment of early Parkinson's disease
46. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
47. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
48. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
49. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
50. Dopamine turnover and glutathione oxidation: Implications for Parkinson disease
51. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
52. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease
53. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays
54. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease
55. Iron in the brain: Implications for Parkinson's and Alzheimer's diseases
56. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?